Sold as Modeyso. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Dordaviprone Hydrochloride (sold as Modeyso), first approved Aug 6, 2025, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Modeyso | Part D | $3.2M | New | 17 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Testing for Safety and Colorectal Cancer Preventive Effects of ONC201Colorectal Adenomatous Polyp, Colorectal Carcinoma · National Cancer Institute (NCI) | Phase 1 | Recruiting | Nov 30, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
